Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof

Details Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof

2004-11-24

2009-02-17

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S185100, C424S190100, C530S350000, C435S007340, C435S007100, C536S023100, C536S023700, C536S024320

Reexamination Certificate

active

07491402

ABSTRACT:
The invention provides superantigens SMEZ-2, SPE-G, SPE-H and SPE-J, as well as polynucleotides which encode them. Such superantigens have, inter alia, diagnostic and therapeutic application.

REFERENCES:
patent: 5545716 (1996-08-01), Johnson et al.
patent: 5698679 (1997-12-01), Nemazee
patent: 5728388 (1998-03-01), Terman
patent: 5858363 (1999-01-01), Dohlsten et al.
patent: 5859207 (1999-01-01), Johnson et al.
patent: 5869207 (1999-02-01), Saidi et al.
patent: 5968514 (1999-10-01), Johnson et al.
patent: 6042837 (2000-03-01), Kalland et al.
patent: 6126945 (2000-10-01), Terman et al.
patent: 6180097 (2001-01-01), Terman
patent: 6197299 (2001-03-01), Dohlsten et al.
patent: 6221351 (2001-04-01), Terman
patent: 6251385 (2001-06-01), Terman
patent: 6338845 (2002-01-01), Terman
patent: 6340461 (2002-01-01), Terman
patent: 6514498 (2003-02-01), Antonsson et al.
patent: 6692746 (2004-02-01), Terman et al.
patent: 7125554 (2006-10-01), Forsberg et al.
patent: 2003/0039655 (2003-02-01), Forsberg et al.
patent: 2003/0092894 (2003-05-01), Antonsson et al.
patent: 2003/0124142 (2003-07-01), Fraser et al.
patent: 2005/0153376 (2005-07-01), Fraser et al.
patent: 2006/0160121 (2006-07-01), Mounts et al.
patent: 2006/0210579 (2006-09-01), Telford et al.
patent: 2006/0210580 (2006-09-01), Telford et al.
patent: 2006/0210581 (2006-09-01), Telford et al.
patent: 2006/0210582 (2006-09-01), Telford et al.
patent: 2006/0246067 (2006-11-01), Fraser
patent: 2006/0258849 (2006-11-01), Telford et al.
patent: 2006/0275315 (2006-12-01), Telford et al.
patent: 2007/0082001 (2007-04-01), Forsberg et al.
patent: 2007/0092528 (2007-04-01), Sun
patent: 0 766 566 (2001-04-01), None
patent: 93/14634 (1993-08-01), None
patent: 9/24910 (1998-06-01), None
patent: 98/26747 (1998-06-01), None
patent: 99/27889 (1999-06-01), None
patent: 02/11619 (2002-02-01), None
patent: WO 02/34771 (2002-05-01), None
patent: 02/45739 (2002-06-01), None
patent: 03/095481 (2003-11-01), None
patent: WO 03/094846 (2003-11-01), None
patent: 03/101173 (2003-12-01), None
Yang et al, J. Clinical Microbiology, Jul. 2005, 43/7:3570-3573 abstract only.
Nooh et al, JBC, Nov. 16, 2006, 281/46:35281-35288.
Stevens et al, J. Immunology, 1996, 157:2479-2487.
Baker et al, JBC, 2004, 279/37:38571-38576 abstract only.
Proft et al, Emerging Infectious Diseases, Oct. 2003, 9/10:1211-1218.
Banks et al, J. Infectious Diseases, 2004, 190:727-738.
Hong-Geller et al, J. Molecular Recognition, 2003, 16:91-101.
Gerlach et al, FEMS Immunology and Medical Microbiology, 2001, 30:209-216.
Igwe et al, FEMS Microbiology Letters, 2003, 229:259-264.
Smoot et al, PNAS, Apr. 2, 2002, 99/7:4668-4673.
Nosoh et al, Protein Stability and Stabilization through protein engineering, 1991, pp. 197-217.
Protein Structure, a practical approach, T.E. Creighton, 1990, pp. 184-186.
Burgess et al, JCB, 1990, 111:2129-2138.
Lazar et al, Molecular and Cellular Biology, 1988, 8:1247-1252.
Kumar et al, PNAS, 1990, 87:1337-1341.
Bixler et al, Synthetic Vaccines, 1987, pp. 39-71.
Bowie et al, Science, Mar. 16, 1990 247:1306-1310.
Houghten et al, Vaccines86, 1986, pp. 21-25.
Proteins, T. E. Creighton, 1984, pp. 314-315.
Stephen C. Goshorn et al. “Nucleotide Sequence of Streptococcal Pyrogenic Exotoxin Type C”. Database Swissprot Accession No. P13380. Infection and Immunity 56(9):2518-2520, 1988.
D. Gerlach et al. “Purification and biochemical characterization of a basic superantigen (SPEX/SMEZ3) fromStreptococcus pyogenes”. Database GenPept, Accession No. CAB51744, Jul. 29, 1999.
D. Gerlach et al. “Biochemical purification and characterization of a basic superantigen ofStreptococcus pyogenes”. Database GenPept, Accession No. CAB51332, Jul. 19, 1999.
D. Gerlach et al. “Purification and biochemical characterization of a basic superantigen (SPEX/SMEZ3) fromStreptococcus pyogenes”. Database GenPept, Accession No. CAB51142, Jul. 19, 1999.
Goshorn, et al. “Nucleotide sequence of streptoccal Pyrogenic Exotoxin type C”. Database Swiss-Prot, Locus SPEC—STRPY, Accession No. P13380, Jan. 1990.
Goshorn, et al. “Nucleotide sequence of streptococcal Pyrogenic Exotoxin type C”. Database GenPept, Accession No. AAB 59091, 1988.
Jodi A. Lindsay et al. “The gene for toxic shock toxin is carried by the family of mobile pathogenicity islands inStaphylococcus aureus”. Molecular Microbiology 29(2):527-543, 1998.
Vivek Kapur et al. “Molecular Population Genetic Evidence of Horizontal Spread of two Alleles of the Pyrogenic Exotoxin C Gene (speC) among Pathogenic Clones ofStreptococcus pyogenes”. Infection and Immunity 60(9):3513-3517, Sep. 1992.
Sibyl H. Munson et al. “Identification and Characterization of Staphylococcal Enterotoxin Types G and I fromStaphlococcus aureus”. Infection and Immunity 66(7):3337-3348, 1998.
Thomas Proft, et al. “Identification and characterization of novel superantigens fromStreptococcus pyogenes”. Journal of Experimental Medicine 189(1):89-101, 1999.
Thomas Proft, et al. Accession No. AAD52087. “Identification and characterization of novel superantigens fromStreptococcus pyogenes”. Journal of Experimental Medicine 189(1):89-101, 1999.
Alain Roussel et al. “Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules”. Nature Structural Biology 4(8):635-643, Aug. 1997.
Thomas Proft, et al.Superantigens: Just Like Peptides Only Different. J. Exp. Med. 187(6):819-821, Mar. 1998.
John K. McCormick, et al.Development of Streptococcal Pyrogenic Exotoxin C Vaccine Toxoids That Are Protective in the Rabbit Model of Toxic Shock Syndrome. Journal of Immunology, 165:2306-2312, 2000.
Arcus et al. “Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens fromStreptococcus pyogens”. J. Molecular Biology 299:157-168, 2000.
Fraser et al. “Superantigens—powerful modifiers of the immune system”. Molecular Medicine 6:125-132, Mar. 2000.
Leder et al. “A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor β chain and major histocompatibility complex class II”. J. Exp. Med. 187(6):823-833, Mar. 1998.
Li et al. “Three-dimensional structure of the complex between a T cell receptor β chain and the superantigen staphylococcal enterotoxin B”. Immunity 9:807-816, Dec. 1998.
Proft et al. “The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation”. J. Exp. Med. 191(10):1765-1776, May 2000.
Unnikrishnan et al. “The bacterial superantigen streptococcal mitogenic exotoxin Z is the major immunoactive agent ofStreptococcus pyogenes”. The Journal of Immunology 169:2561-2569, 2002.
Thomas Proft, et al. “The Streptococcal Superantigen SMEZ Exhibits Wide Allelic Variation, Mosaic Structure, and Significant Antigenic Variation”. J. Exp. Med © The Rockefeller University Press •vol. 191, No. 10, May 15, 2000 1765-1776.
Thomas Proft, et al. “Two Novel Superantigens Found in Both Group A and Group CStreptococcus”. Infection and Immunity, Mar. 2003, p. 1361-1369.
GenBank, Accession No. AAD52087, Authors: Proft, T, Fleming, N and Fraser JD.
GenBank, Accession No. AAD30988, Authors: Proft, T, Fleming, N and Fraser JD.
GenBank, Accession No. AAL31570, Authors: Proft T, Moffatt, SL, Berkahn, CJ and Fraser, JD.
GenBank, Accession No. AAD30989, Authors: Proft, T, Moffatt, SL, Berkahn, CJ and Frser, JD.
Thomas Proft, et al. “Identification and Characterization of Novel Superantigens fromStreptococcus pyogenes”. J. Exp. Med. © The Rockefeller University Press • vol. 189, No. 1, Jan. 4, 1999 89-101.

Affiliated with

Also associated with

Rating

Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4125523